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ARTICLE
Single cell sequencing reveals endothelial plasticity
with transient mesenchymal activation after
myocardial infarction
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Endothelial cells play a critical role in the adaptation of tissues to injury. Tissue ischemia
induced by infarction leads to profound changes in endothelial cell functions and can induce
transition to a mesenchymal state. Here we explore the kinetics and individual cellular
responses of endothelial cells after myocardial infarction by using single cell RNA sequencing.
This study demonstrates a time dependent switch in endothelial cell proliferation and
inflammation associated with transient changes in metabolic gene signatures. Trajectory
analysis reveals that the majority of endothelial cells 3 to 7 days after myocardial infarction
acquire a transient state, characterized by mesenchymal gene expression, which returns to
baseline 14 days after injury. Lineage tracing, using the Cdh5-CreERT2;mT/mG mice followed
by single cell RNA sequencing, confirms the transient mesenchymal transition and reveals
additional hypoxic and inflammatory signatures of endothelial cells during early and late
states after injury. These data suggest that endothelial cells undergo a transient mes-
enchymal activation concomitant with a metabolic adaptation within the first days after
myocardial infarction but do not acquire a long-term mesenchymal fate. This mesenchymal
activation may facilitate endothelial cell migration and clonal expansion to regenerate the
vascular network.
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The endothelium forms the inner layer of blood vessels andshows remarkable plasticity and heterogeneity in structureand function, in health and disease. Endothelial cells (ECs)
form a vascular plexus during early development and differentiate
into arterial, venous or lymphatic fates to establish a circulatory
network. At later states, endothelial cells acquire organ specific
properties essential for maintaining the function of the individual
organs1,2. Certain ECs within the endocardium undergo a process
named endothelial–mesenchymal transition (EndMT), to give
rise to mesenchymal cells which are necessary for proper heart
and valve development3–5. Transitions of endothelial cells to
hematopoietic cells also occurs in embryonic development4,6.
Throughout life, endothelial cells are exposed to various
mechanical, inflammatory, and metabolic environments. Pheno-
typic changes are facilitated by high low-density lipoprotein
(LDL) cholesterol, a pro-inflammatory state and turbulent flow
patterns leading to endothelial activation. This contributes to the
impairment of the vasodilatory activity (so called “endothelial
dysfunction”), which plays a key role in the development of
atherosclerotic lesions7. Switches in endothelial phenotypes
additionally occur during blood vessel growth, which involves a
critically fine-tuned and transient specialization of endothelial
cells8. Endothelial “tip” cells migrate at the forefront and are
followed by “stalk” cells, which elongate the sprout. The tip-stalk
cell phenotype dynamically switches under control of vascular
endothelial growth factor (VEGF) and Notch and involves
metabolic reprogramming8–10. Recent single-cell RNA sequen-
cing studies provide further insights into the heterogenic gene
expression signatures of ECs in tumors, leading to the identifi-
cation of metabolic plasticity and collagen modification as
potential critical angiogenic players11,12. Under pathological pro-
inflammatory conditions associated with high TGF-β2 levels,
endothelial cells can undergo EndMT in adulthood4. EndMT was
reported in tumors and was suggested to contribute to
atherosclerosis13,14 and myocardial fibrosis after cardiac stress or
injury15,16. However, recent fibroblast lineage tracings analyses
suggest that the overall contribution of endothelial cells to the
cardiac fibroblast population is limited17,18. A partial mes-
enchymal transition or mesenchymal activation may also con-
tribute to (patho)physiological vessel growth by facilitating a pro-
migratory and pro-invasive EC phenotype19. In support of a role
of mesenchymal activation of ECs in vessel growth, we recently
demonstrated that clonally expanding ECs in ischemic tissue
express mesenchymal markers20. However, the molecular sig-
natures and plasticity of endothelial cells in response to ischemia
in vivo are not well established. Here we show the adaptive
responses of ECs to cardiac ischemia by using single-cell tech-
nology, a powerful tool capable of deciphering individual cellular
responses and transcriptional signatures within tissue.
Results
Kinetics of EC inflammation, survival, and proliferation.
Single-cell RNA sequencing of the non-cardiomyocyte fraction of
murine hearts was performed at day 0 (homeostasis) and at day 1, 3,
5, 7, 14, 28 post myocardial infarction (MI)21. This revealed 19 cell
clusters including 4 clusters of endothelial cells (demarcated by Cdh5
and Pecam1 expression), 6 fibroblast clusters, and 7 clusters of
hematopoietic cells (Fig. 1a, b and Supplementary Fig. 1a). Consistent
with induction of myocardial damage, total cell numbers declined
from day 1 to 7 but controls confirmed that the quality of the
sequencing and cell type annotations is comparable in all samples
(Supplementary Table 1, Supplementary Fig. 1b, and Supplementary
Data 1). The relative abundance of endothelial cells and mesenchy-
mal cells declined during the first week after MI, corresponding with
an influx of immune cells at early time points (Fig. 1c). Significantly
augmented GO terms in EC clusters at day 1 post MI include the
cellular response to hypoxia, positive regulation of inflammatory
response, programmed cell death and angiogenesis (Fig. 1d).
Representative genes of these pathways include the apoptosis related
genes Bax and Trp53, the hypoxia induced factorsHif1a and Ldha, as
well as the inflammatory cytokines Il1b, Il6, and Tnf (Fig. 1e).
Between day 1 and 7, genes associated with epithelial mesenchymal
transition, extracellular matrix organization and cellular proliferation
were significantly enriched (Fig. 1d). The increase in EC proliferation
was confirmed by bioinformatic analysis of cell cycle phases showing
an increase in expression of cell cycle genes and number of ECs in
S-phase at day 3, which is returned to homeostatic levels at day 14
after MI (Fig. 1f, g). Phospho histone H3 staining and published
data22 confirm an increased proliferation of endothelial cells at day 3
(Supplementary Fig. 2). Interestingly, the cellular response to nitric
oxide was repressed between days 1 and 14 (Fig. 1d).
ECs acquire a transient state of mesenchymal transition after
MI. Next we used single-cell trajectory analysis to identify in an
unbiased manner the different states which ECs acquired after
MI. We could identify 5 states that are populated by Cdh5 and
Pecam1 expressing ECs (Fig. 2a and Supplementary Fig. 3a). MI
induced an increase in ECs associated with state 3, which is a
predominantly pro-inflammatory state characterized by pathways
involved in neutrophil activation, inflammatory response and
cytokine signaling (Fig. 2a, b and Supplementary Fig. 3a–d). The
majority of ECs during the first week after MI, however, were
found in state 4, which is characterized by the GO term extra-
cellular matrix (Fig. 2b, Supplementary Fig. 3a, and Supplemen-
tary Fig. 3c). Specific genes enriched in state 4 include
mesenchymal genes, cell cycle and proliferative genes, whereas
transcripts involved in fatty acid up-take and signaling were
down-regulated (Fig. 2b). The expression of these genes resembles
the signature of EndMT or ECs undergoing mesenchymal acti-
vation. Representative upregulated genes of state 4 including
Col3a1, Fn1 Serpine1 and others as shown in Fig. 2c, d. Endo-
thelial marker genes, such as Cdh5 were down-regulated (Fig. 2c)
in state 4. The induction of mesenchymal markers at day 3 after
MI was confirmed by bulk RNA sequencing of isolated Cdh5+
cells (Fig. 2e). Interestingly, cell numbers in state 4 were only
increased between days 1 and 7 and returned to baseline levels
after 14 days (Fig. 2a). A similar kinetic was observed when
analyzing the total EC population (clusters 6, 7, 17, and 18) for
changes in EC or mesenchymal marker expression across MI time
points (Fig. 2f, g). This suggests that EC acquire a transient
mesenchymal activation (EndMA) state in the first week after MI.
Using a different bioinformatic analysis strategy by re-clustering
the EC population, cells were separated into ECs lacking
mesenchymal markers, lymphatic ECs (cluster 9), and ECs
expressing mesenchymal genes (cluster 4–6; Supplementary
Fig. 4a, b). We observed a similar loss of endothelial gene
expression and gain of mesenchymal genes when excluding
lymphatic ECs and the other non-EC cluster 11 and 12 from the
analysis (Supplementary Fig. 4c, d). At early time points (d1–d7),
ECs dominantly populated in clusters with mesenchymal genes
and constitute the majority of EndMA cells. Moreover, this
population showed more cells in state 4 of the trajectory analysis
(Supplementary Fig. 4e–g), confirming the transient nature of
EndMA. Consistently, mesenchymal protein expression in
endothelial cells at days 3–7 after infarction was induced as
assessed by immunostaining (Supplementary Fig. 5 and Supple-
mentary Fig. 6a, b) and FACS analysis (Supplementary Fig. 6c).
Furthermore, we exclude the possibility that EndMA cells may be
simply removed by cell death, since we could not find Caspase3-
positive endothelial cells expressing mesenchymal marker (Sm22)
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at d3 and d7 after infarction (Supplementary Fig. 7a) or
enrichment for apoptosis specific gene signatures in EndMA cells
(Supplementary Fig. 7b).
To provide further evidence that mesenchymal cells can revert
to an endothelial cell phenotype, we performed collagen-tracing
studies in Col1a2-CreERT2;mT/mG mice, traced at day 3 to day 7
after infarction (Supplementary Fig. 8a). Then we performed
single-cell RNA sequencing and histology at day 28. Indeed,
GFP+ cells were detectable in the endothelial cluster (Supple-
mentary Fig. 8b), demonstrating that Col1a2 traced cells can
become transcriptionally similar to endothelial cells between day
7 and day 28 after infarction. These results were confirmed by
histology showing GFP expressing cells, which co-express the
endothelial marker Isolectin B4 (Supplementary Fig. 8c).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-20905-1 ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:681 | https://doi.org/10.1038/s41467-021-20905-1 | www.nature.com/naturecommunications 3
To test if mesenchymal activation may contribute to endothelial
proliferation and expansion, we inhibited mesenchymal transition
with the TGF-β-inhibitor Galunisertib (LY2157299)23. We then
assessed clonal expansion of ECs after MI using Confetti mice
as previously described20. TGF-β-inhibitor treatment reduced
the incidence of clonal expansion in Confetti mice 7 days after
MI in the border zone by 79 ± 19% compared to infarcted controls
(p= 0.03; Supplementary Fig. 9), suggesting that mesenchymal
activation contributes to endothelial expansion.
Characterization of EndMA cells. To further characterize the
ECs undergoing EndMA, we compared the transcriptome of
endothelial cells, which express mesenchymal markers, to endo-
thelial cells lacking the expression of these marker genes. As
expected, EndMA cells showed a high expression of mesenchymal
and extracellular matrix genes (Fig. 3a), enriched expression of
genes associated with epithelial mesenchymal expression (Sup-
plementary Fig. 10a, b) and GO terms associated with extra-
cellular matrix organization, Pdgf binding, collagen synthesis, and
organization (Fig. 3b). In contrast, ECs which are not undergoing
EndMA showed high expression of genes involved in fatty acid
signaling, ECs enriched transcription factors and GO terms
associated with VEGF and VEGF-receptor response, carbohy-
drate transport, Wnt signaling, vascular development, and
negative regulation of EC proliferation (Fig. 3a, b). The expres-
sion of metabolism-associated genes differs between EndMA
positive and negative ECs. Since EC metabolism is known to play
a critical role in endothelial plasticity and EndMT24, we per-
formed a detailed analysis of the gene expression signatures
related to glycolysis, citric acid cycle, glutamine, pentose phos-
phate pathway and fatty acid signaling (Fig. 3c). EndMA cells
showed a high expression of glycolysis genes (Fig. 3c and Sup-
plementary Fig. 10a), whereas the expression of fatty acid sig-
naling, and tricarboxylic acid (TCA) cycle genes was reduced
compared to ECs, which do not express mesenchymal markers
(Fig. 3c), suggesting a metabolic switch from fatty acid towards a
glycolytic metabolism during EndMA. Interestingly, analysis of
the time course after MI demonstrates a transient switch of EC
metabolism during days 1–3. Early induction of glycolysis genes
at day 1 and a reduction of fatty acid signaling associated genes,
such as Fabp4 at day 3 (Fig. 3d and Supplementary Fig. 11),
documented an adaptation of EC metabolism during the time
frame in which mesenchymal activation occurs. In vitro studies
confirmed the induction of glycolysis upon TGF-β2-stimulation
of endothelial cells (Supplementary Fig. 12a). Interestingly,
carbon-13 glucose tracing confirmed the increasing utilization of
glucose for glycolysis without effects on glucose uptake (Supple-
mentary Fig. 12b).
EndMA may not only change intrinsic cell functions but also
may affect cell-to-cell communication. To explore whether
EndMA affects the interaction of ECs with other cells in the
heart, we used bioinformatic assessment of ligand-receptor
relations25. Weighted analysis of such interactions revealed that
EndMA cells showed higher ligand-interaction relations com-
pared to EndMA negative cells (Supplementary Fig. 13a, b).
EndMA cells showed increased outgoing signals involved in genes
associated with the GO terms of extracellular matrix organization,
Pdgf binding, and collagen fibril organization (Supplementary
Fig. 13b–d). Analysis of the specific cell communication
signatures between the cells revealed that EndMA cells overall
have higher outgoing signals, particularly to ECs lacking
mesenchymal markers (Supplementary Fig. 13a), suggesting that
EndMA may affect the cell-to-cell communication in the heart
after MI.
Cdh5-lineage tracing confirms the transient nature of EndMA
after MI. Our data suggest that MI induces a transient metabolic
and phenotypic switch in endothelial cells associated with EndMA.
However, in the absence of lineage tracing, we may have missed
ECs which fully transit to a mesenchymal phenotype and lost EC
marker gene expression. To characterize the long-term fate of ECs,
we used endothelial fate-mapped mT/mG reporter mice (Cdh5-
CreERT2;mT/mG). Tamoxifen injection led to the expected induc-
tion of GFP in endothelial cells (Fig. 4a, b and Supplementary
Fig. 14a). Analysis of GO terms associated with GFP+ cells after MI
showed an early increase in pathways associated with cell death,
response to hypoxia, and proliferation in early stages, as well as GO
terms associated with augmented extracellular matrix and epithelial
mesenchymal transition at later stages (Supplementary Fig. 14b).
Thus, GFP+ cells showed similar gene expression signatures as the
non-traced endothelial cells (Fig. 1d), supporting the hypothesis
that EndMA is a transient phenomenon.
To determine the kinetics of EndMA, we assessed the
expression of mesenchymal markers in GFP+ cells at each
timepoint. Interestingly, the number of GFP+ cells expressing the
endothelial marker Cdh5 and mesenchymal markers, such as
Col1a1, Col3a1, or Serpine1, augmented transiently with a
maximum between days 3 and 7 (Fig. 4d). At later timepoints,
we did not observe an increase in fully transited mesenchymal
GFP+ cells lacking ECs markers (Fig. 4d, right panels).
In addition, we used an unbiased approach to determine the
occurrence of GFP-traced EndMA cells after MI. Re-clustering of
GFP+ cells led to the identification of a cluster of EndMA
resembling cells (cluster 6), which showed a high expression of
collagens but low expression of endothelial marker genes
(Fig. 4e–g). Interestingly, the proportion of cells in cluster 6
Fig. 1 Myocardial infarction induces various changes in endothelial cells. a tSNE plot from pooled single-cell RNA sequencing data of non-
cardiomyocytes from hearts after myocardial infarction (MI). Homeostasis (Hom), day(d) d1, d3, d5, d7, d14, and d28 post MI cardiovascular cells (n=
35,312 cells; n= 1 mouse per time point). We found seven cell types: fibroblasts (Fb), monocytes (Mono), endothelial cells (Ec), B-cells, T-cells, smooth
muscle cells (Smc), and unknown (U). b tSNE plot highlighting scaled and normalized UMI counts for endothelial genes Cdh5 (VE-cadherin) and Pecam1
(CD31). c Kinetic of proportion of endothelial cells, macrophages, and mesenchymal cells relative to total number of cells per timepoint. Cell types were
annotated based on Seurat’s clustering in a and markers as described in (Supplementary Fig. 1a). Data represent n= 1 mouse per timepoint, n= 4219
endothelial cells, n= 10,347 macrophages, n= 17,459 mesenchymal cells. d GO-Term enrichment of genes significantly regulated (Bonferroni adjusted
p < 0.05) over time course in endothelial cells (Pecam1+/Cdh5+). Color indicates combined enrichment score (based on Enrichr software). Size indicates
number of significant regulated genes per total genes in GO-Term. e Relative number of endothelial cells expressing (UMI≥ 1) apoptosis marker genes
(Bcl2-associated protein X; Bax and p53; Trp53), hypoxia marker genes (Hypoxia inducible factor; Hif1a and lactate dehydrogenase A; Ldha) and
inflammation marker (Interleukin 1b and 6; Il1b and Il6 and tumor necrosis factor alpha; Tnf). Data represent n= 1 mouse per timepoint, n= 2905
Pecam1+/Cdh5+ positive cells. f Assignment of endothelial cell phase by Seurat’s ‘CellCycleScoring’ function. Data is presented as percentage per
timepoint. P-value was calculated using Chi-squared test of independence with Yates correction, p= 0.0004. Data represent n= 1 mouse per timepoint,
n= 2905 Pecam1+/Cdh5+ positive cells. g Individual fold change to homeostasis of significant (Bonferroni adjusted p < 0.05) markers for S-phase and
G2/M-phase in d3 endothelial cells. Data shown as mean ± SEM. Data represent n= 1 mouse per timepoint, n= 2905 Pecam1+/Cdh5+ positive cells.
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was higher at day 7 (Fig. 4g), consistent with a transient
mesenchymal transition of ECs after MI.
Mesenchymal transition is reversible in vitro. Our data suggest
that ECs transiently acquire a reversible partial mesenchymal
state after MI in vivo. To gain further insights into the
reversibility of EndMT in vitro, we incubated ECs with TGF-β2
for 3 days and withdrew the stimulus. After 3 days of TGF-β2
treatment, ECs express the mesenchymal marker genes calponin
(CNN1) and SM22 (TAGLN) (Fig. 4h, i, and Supplementary
Fig. 15a–c). The withdrawal of TGF-β2 induced the reversion of
mesenchymal marker gene expression to baseline levels within
7 days, whereas continuous incubation with TGF-β2 led to a
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Fig. 2 Endothelial cells gain mesenchymal markers at day 1–7 after myocardial infarction. a Pseudo-time trajectory analysis of endothelial cells (ECs),
using significantly regulated genes between timepoints. Pie charts showing how many cells were assigned to each cluster relative to the total number of
cells per timepoint. (n= 2905 cells, ECs were selected from data shown in Fig. 1b). b Dot plot showing fold-change (blue to red) of marker genes
associated with fatty acid oxidation, mesenchymal identity, and cell cycle proliferation between trajectory states shown in a. Size indicates adjusted p-value
for each gene in log10 scale. c Violin plot showing increased values of normalized UMI counts for mesenchymal markers (Col3a1 and Serpine1) and
decreased values for endothelial marker (Cdh5) in trajectory state 4 (n= 694 cells), compared to other states (n= 2111 cells, p= 3.3 × 10−76 (Col3a1), p=
2.6 × 10−27 (Serpine1), p= 1.7 × 10−75 (Cdh5), bimodial likelihood-ratio test, Bonferroni adjusted p-values) d EndMT marker show significant upregulation
between d1–d7 in ECs compared to baseline (homeostasis). Data is presented in average fold-change to homeostasis, mean ± standard deviation. e Bulk-
RNA sequencing analysis of isolated endothelial cells comparing homeostasis (n= 4) and d3 after acute myocardial infarction (AMI; n= 3). Color indicates
column-wise z-score (blue to red). f Heatmap of various endothelial marker, showing reduction of mean UMI levels at d1–d7 after infarction in ECs. Upper
panel represents the mean z-score of all four endothelial markers per time point. Data is presented as mean ± SEM. g Comparison of Pecam1 (endothelial
marker) and Fn1 (mesenchymal marker) levels. Every point indicates an individual cell. Boxes (quadrants, Q1 and Q3) show cells which are expressing the
marker strongly (top 50% of all non-zero values). Percentage values are indicative of how many cells per timepoint are grouped in the respective box. Data
represent n= 1 mouse per timepoint, Homeostasis n= 592 cells, d1 n= 71 cells, d3 n= 70 cells, d5 n= 181 cells, d7 n= 277 cells.
Fig. 3 Activated endothelial cells show distinct transcriptional phenotypes. a Dot plot showing significant change (Bonferroni adjusted p < 0.05) of
various mesenchymal, metabolism, and transcription factor genes in Pecam1+/Cdh5+/Serpine1+/Fn1+ cells (EndMA+) compared to other endothelial cells
(Pecam1+/Cdh5+/mesenchymal marker-; EndMA−) cells. Color indicates log-fold change (red to gray), size depicts significance level (log10 p-value). b Top
10 enriched GO-terms ranked by Enrichr’s combined score for genes, significantly upregulated in EndMA+ and EndMA−, respectively. c, d Heatmap
showing gene regulation of genes associated with fatty acid (FA) signaling, pentose phosphate pathways (PPP), glutamine metabolism, tricarboxylic acid
(TCA) cycle and glycolysis pathway comparing EndMA+, and EndMA− and all other cells in the dataset (c) at the indicated time points in endothelial cells
(d). Data is presented in row-wise z-score.
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further increase in mesenchymal marker gene expression (Fig. 4h,
i). Similar findings were observed when inducing mesenchymal
transition by a combination of TGF-β1, IL-1b and the nitric oxide
synthase inhibitors (N-Nitroarginine methyl ester; L-NAME)
(Supplementary Fig. 15d, e). Notably, mesenchymal gene
expression induced by prolonged incubation with TGF-β2 for up
to 10 days was reversed by replacement of the stimulus to control
medium without TGF-β2 (Supplementary Fig. 15f, g). The
reversible nature of EndMA was further supported by the coin-
ciding metabolic adaptation of endothelial cells. TGF-β2 treat-
ment induced the upregulation of glucose metabolism, which was
fully reversed upon withdrawal to control medium (Supplemen-
tary Fig. 12b). To exclude that mesenchymal marker expressing
endothelial cells are outcompeted by remaining endothelial cells,
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we additionally treated TGF-β2 stimulated cells with a cell cycle
inhibitor and assessed the effect on the reversibility. However, cell
cycle inhibition did not affect reversibility of EndMT (Supple-
mentary Fig. 16).
To assess if TGF-β2 treatment leads to a true fate change, we
analyzed DNA methylation of mesenchymal genes. We did not
observe changes in DNA methylation levels in gene bodies within
the mesenchymal genes COL4A1, TAGLN, and CNN1 after TGF-β2
stimulation and withdrawal (Supplementary Fig. 17a–c). However,
we observed a reversible demethylation of regulatory regions upon
TGF-β2 stimulation (Supplementary Fig. 17d). These observations
confirm that mesenchymal gene expression induced by several
different protocols is reversible and is associated with changes in
DNA methylation of regulatory regions.
Discussion
The presented study provides a detailed analysis of EC gene
expression signatures after cardiac ischemia. We demonstrate that
ECs undergo a transient mesenchymal activation that is associated
with profound metabolic adaptations (Supplementary Fig. 18). The
transient nature of mesenchymal gene expression in endothelial
cells was supported by Cdh5-lineage tracing studies, which
demonstrated that Cdh5-traced cells transiently express transcripts
typically associated with EndMT. Mesenchymal transcript expres-
sion in Cdh5-traced cells returns to levels detected in homeostasis
condition after more than 10 days post-myocardial infarction.
Interestingly, the majority of mesenchymal gene expressing GFP+
traced cells retain a low expression of endothelial genes (Fig. 4d),
suggesting that they undergo a transient EndMA rather than full
EndMT. In support of a partial transition, our data show that most
EndMA cells express modest levels of mesenchymal marker genes
in comparison to bona fide fibroblasts (Supplementary Fig. 19).
Consistent with our data demonstrating that only few GFP-traced
cells fully lose their endothelial signature and express high levels of
mesenchymal genes, recent single-cell RNA sequencing studies also
failed to detect significant numbers of cells undergoing a full
mesenchymal transition after myocardial infarction26. Initial studies
have imposed the concept, that the conversion of endothelial cells to
mesenchymal cells was a permanent shift between two differ-
entiated cellular states. However, in the context of cardiac ischemia
our study suggests that EndMA likely represents a reversible con-
tinuum in response to a hypoxic and inflammatory injury envir-
onment, instead of a differentiation process in its classical sense.
This model is consistent with our in vitro study clearly doc-
umenting a reversible nature of EndMA after removal of EndMT
promoting stimuli. Interestingly, similar findings on endothelial
cells were already reported in 1992, demonstrating that withdrawal
of TGF-β1 after 10 days incubation resulted in the re-appearance of
polygonal cells with an endothelial phenotype27. However, the
mechanisms by which this switch back to an endothelial phenotype
occurs and if this includes epigenetic changes is unclear. Our
in vitro experiments utilizing endothelial cells did not show changes
in DNA methylation patterns at promoters of mesenchymal genes
after TGF-β2 stimulation, suggesting that a true transition to a
mesenchymal phenotype driven by epigenetic changes at the level of
DNA methylation is a rare event under these conditions. We also
did not observe a hypermethylation of RASAL1, which was shown
to be induced after long-term treatment of ECs with TGF-β1 for
12 days28. Instead, we found a reversible methylation pattern at
several regulatory elements, but the potential functional implica-
tions of those methylation events need to be studied in more detail.
What is the physiological or pathophysiological relevance of
this transient EndMA? The partial EndMA may contribute to
new blood vessel growth, by promoting a pro-migratory and pro-
invasive state. Indeed, EndMA cells show signatures of genes
associated with extracellular matrix organization, migration and
proliferation, and the inhibition of TGF-β signaling reduced
expansion of endothelial cells. Reports of the literature also
support such a model, as it has been demonstrated that inhibition
of EndMT driving transcription factors such as Snail or Slug
prevents EC migration and in vitro angiogenesis29 and clonally
expanded ECs showed a high expression of EndMT marker
genes20. On the other hand, even the partial induction of EndMA
may have detrimental effects. Although, our studies suggest that
the direct contribution of EndMA to cardiac fibrosis by transition
of ECs to cardiac fibroblasts is limited, we cannot exclude that
cells undergoing EndMA may secrete extracellular matrix and
inflammatory proteins, which affect the wound healing response
and may thereby indirectly contribute to fibrosis. A transient
mesenchymal activation may also contribute to other pathological
states in vascular disease, such as atherosclerosis. As mesenchy-
mal transition is associated with cellular detachment30 one might
envision a role in the acute events leading to plaque erosion.
Together, our study demonstrates a transient mesenchymal
activation of endothelial cells and may clarify some controversies
in the literature. While our RNA single-cell sequencing study
clearly confirms the existence of mesenchymal marker expressing
cells, and therefore supports the many studies reporting
endothelial-mesenchymal transitions31, this process appears
reversible and therefore was not found to occur in long-term fate
studies using lineage tracing. Future investigations may provide
insights as to what extent EndMA (as opposed to EndMT) occurs
in other injury or disease conditions and how risk factors
affecting the stability of the endothelial epigenome may be able to
interfere with the reversibility of the process.
Methods
Animals. All animal experiments were executed in agreement with the animal
welfare guidelines and German national laws. All animal experiments and study
protocols were authorized by the competent authority (Regierungspräsidium
Darmstadt, Hessen, Germany). Mice were held at 23 °C ambient temperature and
Fig. 4 EndMA is a reversible activation of endothelial cells. a tSNE plot showing all sequenced cells for all timepoints (Homeostasis, d1, d3, d7, d14, d28)
in hearts of tamoxifen treated Cdh5-CreERT2;mT/mG animals (n= 15,365 cells, 1 mouse per time point). We found four mesenchymal clusters (0,1,3,9),
three endothelial clusters (2,8,13), three macrophage/monocyte clusters (4,7,11), four clusters of smooth muscle cells/pericytes (10,14,15,16), two clusters
of T-cells (6,12), and one cluster of B-cells (5). b tSNE plot showing GFP+ traced endothelial cells (n= 1393 cells). c tSNE plot highlighting expression levels
of endothelial marker (Pecam1, Cdh5, Vwf) and mesenchymal marker (Col1a1, Pdgfra, Serpine1) as scaled normalized UMI. d Left panel (green) displays
relative number of cells expressing (UMI≥ 1) GFP, Cdh5, and the mesenchymal markers (Col1a1, Serpine1, or Col3a1) per timepoint. Right panel (blue) shows
population of cells not expressing Cdh5 in this context. Data represents n= 1 mouse per timepoint. Homeostasis n= 592 cells, d1 n= 87 cells, d3 n= 44
cells, d7 n= 166 cells, d14 n= 304 cells, d28 n= 270 cells. e tSNE plot of reclustered GFP positive cells, showing 7 independent clusters. f Gene expression
of different marker genes in different cluster shown in e. Color indicates the log-fold change (blue to red), size shows log p-value. g Relative number of cells
assigned to the different clusters from (e) in homeostasis and d7. h, i Fold change of SM22 (TAGLN) (h) and Calponin (CNN1) (i) mRNA levels measured
by qRTPCR (n= 3 independent experiments) in HUVECs treated with TGF-β2 supplemented medium (turquoise) and control medium (gray). Expression
values were normalized to RPLP0. HUVECs cultured for 3 days in TGF-β2 and subsequent cultivation in control medium until 7 days are shown in green.
P-value was calculated using Kruskal–Wallis test (p= 0.005 SM22, p= 0.006 CNN1). Data shown as mean ± SEM.
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60% humidity in 10 h/14 h light/dark cycle. C57BL/6 J Cdh5-CreERT2 mice
(obtained from The Jackson Laboratory, MGI:3848982) or C57BL/6 J Col1a2-
CreERT2 mice (obtained from The Jackson Laboratory, Stock No. 029235), were
bred with mTomato/mGFPfl/fl (mT/mG) mice (obtained from The Jackson
Laboratory) to generate Cdh5-ERT2+/-;mT/mG or Col1a2-CreERT2+/-;mT/mG
mice. For Cdh5-ERT2+/-;mT/mG, mice were used at an age of 10–12 weeks (n= 6,
male mice). Cre expression was induced by daily intraperitoneal injections of
2 mg/mouse tamoxifen (T5648; Sigma Aldrich) for 1 week in all mice. One week
after tamoxifen injection, left anterior descending (LAD) coronary artery ligation
surgery was performed, inducing myocardial infarction (MI) as previously
described32. The animals were anesthetized with isoflurane and analgesia was
delivered by an intraperitoneal injection of Buprenorphin (0.1 mg/kg body weight
(BW)) in combination with a block of the intercostal nerves by using Bupivacaine
(1 mg/kg BW, 0.25% Bupivacaine). For postoperative analgesia, Buprenorphin and
Caprofen (5 mg/kg BW) were given every 12 or 24 h for 3 days. Postoperative
infection was prevented by giving Ampicillin (100 mg/kg BW) via drinking water.
Under mechanical ventilation, the MI was induced by permanent ligation of the left
anterior descending coronary artery. Echocardiography was performed on day 0 to
ensure the induction of a MI using the program VevoLab (Visualsonics). After days
1, 3, 7, 14, or 28 post MI, hearts were harvested for single-cell RNA sequencing. For
Col1a2-ERT2+/-;mT/mG, LAD surgery was performed and tamoxifen was injected
from 3–7 days post infarction. Hearts were collected 28 days after infarction. For
immunofluorescence stainings, we used wildtype BL6 C57BL/6 J animals (without
tamoxifen treatment) undergoing the same experimental procedure.
For Galunisertib LY2157299 (A11017, AdooQ) in vivo treatment, we injected
tamoxifen in Confettifl/wt-Cdh5-CreERT2 and induced MI 6 days after last
treatment20. Formulations were prepared in vehicle buffer containing 0.5%
carboxy-methyl cellulose (3333.1, Carl Roth). Suspensions were administered per
oral gavage (75 mg/kg) 2 h before, 24 h after MI and then twice a day. Seven days
after MI, hearts were harvested, as described above.
Single-cell RNA sequencing. For the first analysis shown in Figs. 1–3, we used a
publicly available data set21. For the lineage tracing studies, hearts were digested
with Multi Tissue Dissociation Kit 2 (130-110-203, Miltenyi), as described for
application of dissociation of adult mouse heart. In brief, after flushing murine
hearts with HBSS, hearts were harvested, immediately minced and transferred to an
enzyme mix and dissociated using the gentleMACS Dissociator as described in
the manufacturer’s protocol. Samples were filtered through a MACS SmartStrainer
(70 μm) with 3 mL of PBS with 20% FBS. Samples centrifuged and the resultant
supernatant aspirated. The cell pellet was resuspended in PEB buffer and 1× Red
Blood Cell Lysis Solution to remove erythrocytes. Following erythrocyte removal,
Enzyme A of the Multi Tissue Dissociation Kit 2 was added to PBS in a fresh tube
and then combined with the cell pellet. Following this step, cells were resuspended
in Dead Cell Removal MicroBeads (130-090-101, Miltenyi). Samples were mixed
and incubated following Miltenyi’s protocol instructions. We made the positive
selection with a column of type MS (for up to 107 dead cells and up to 2 × 108 total
cells). Prior to its use, the column was rinsed with binding buffer. Effluent was
collected as the live cell fraction. Cells were counted using Trypan blue and a
Neubauer chamber. Cells were then resuspended appropriately for loading on the
10X Genomics Chromium Controller chip. Resulting non-cardiomyocyte cellular
suspensions were loaded on a 10X Chromium Controller (10X Genomics)
according to manufacturer’s protocol. Murine scRNA-seq libraries were prepared
using Chromium Single Cell 3′ v3 Reagent Kit (10X Genomics), according to
manufacturer’s protocols. Briefly, the initial step consisted in generating cell par-
titioning droplets where individual cells were isolated together with gel beads
coated with unique primers bearing 10X cell barcodes, UMI (unique molecular
identifiers) and poly(dT) sequences. Reverse transcription reactions were engaged
to generate barcoded full-length cDNA followed by the disruption of emulsions
using the recovery agent and cDNA clean up with DynaBeads MyOne Silane Beads
(37002D, Thermo Fisher Scientific). Bulk cDNA was amplified using a Biometra
Thermocycler Professional Basic Gradient with 96-Well Sample Block (98 °C for
3 min; cycled 14×: 98 °C for 15 s, 67 °C for 20 s, and 72 °C for 1 min; 72 °C for 1
min; held at 4 °C). Amplified cDNA product was cleaned with the SPRIselect
Reagent Kit (B23318, Beckman Coulter). Indexed sequencing libraries were con-
structed using the reagents from the Chromium Single Cell 3′ v3 Reagent Kit as
follows: fragmentation, end repair and A-tailing; size selection with SPRIselect;
adapter ligation; post-ligation cleanup with SPRIselect; sample index PCR and
cleanup with SPRI select beads. Library quantification and quality assessment was
performed using Bioanalyzer Agilent 2100 using a High Sensitivity DNA chip
(5067-4627 Agilent Genomics). Indexed libraries were equimolarly pooled and
sequenced by GenomeScan (Leiden, Netherlands).
Single-cell RNA-seq outputs were processed using the CellRanger (10X
Genomics) suite versions 3.0.1. For mapping reads from tracing experiments we
modified the mm10 (GRCm38.p4, version 1.2.0) reference genome and added
sequences of EGFP and tdTomato, obtained from the original vector which had
been used to create the mouse line33, as part of a virtual non-existing chromosome.
We annotated these sequences in the GTF (gene transfer format) file and rebuild
the reference genome by the mkref command implemented in the CellRanger
software. We confirmed the specificity by mapping to data obtained from wildtype
animals or either tamoxifen injected or non-injected Cdh5-CreERT2.
Raw base count files were demultiplexed and processed by mkfastq
implemented in the CellRanger software. Raw reads were then mapped to the
customized reference genome by using CellRanger count. Secondary analysis was
conducted using the Seurat 2.3.4 package in R34. We filtered the data for cells
expressing at least 200 genes, as suggested by the distributer’s tutorial (satijalab.
org). In order to avoid analyzing doublets or dead cells, we removed barcodes with
a high mitochondrial content (>10% of total UMI) as well as barcodes with
abnormal high (upper 5% of all cells) or low (lower 1% of all cells) number of UMI
or genes, respectively. The remaining matrix was log-normalized and scaled.
Genes that were detected as variable in each sample, were then used for
alignment of subspaces in a canonical correction analysis (CCA) as implemented in
Seurat. Number of subspaces were estimated by the “MetageneBicorPlot” function.
We aligned 25 subspaces and set the resolution parameter of FindCluster to 0.6. We
used t-distributed stochastic neighbor embedding (t-SNE) to visualize cell clusters.
Cell cycle states of each cell were predicted by the algorithm implemented in
Seurat35. The cell cycle score was based on mouse orthologous genes to the default
human genes.
For building endothelial subsets based on expression of marker genes we filtered
cells which express Cdh5 and Pecam1 (UMI > 0). In data from lineage tracing
experiments we used a dynamic threshold to separate EGFP positive cells. Based on
the density distribution of EGFP normalized UMIs for each sample we calculated a
cutoff that separated real GFP expressing cells (population with highest EGFP
normalized UMI counts) from false positive based on a local minimum. We
successfully validated this method and estimated the number of GFP positive cells
for a sample which had not been injected with tamoxifen at almost 0.
Gene ontology enrichment analysis have been performed with Enrichr36
(R package version 1.0.) We used GO_Biological_Process_2018 and
GO_Molecular_Function_2018 distributed via the Enrichr webpage and provided
from the gene ontology consortium as our reference gene-set libraries. GO terms
have been ranked and displayed by their “Combined Score” as implemented in
Enrichr, which combines the z-score of the term’s deviation to it’s expected rank
and the p-value from Fisher’s exact test and their specificity score as the fraction of
genes enriched to the total number of genes in the respective GO term. Gene set
enrichment analysis was performed using clusterProfiler (R package version 3.10.1)
and gene sets from Molecular Signatures Database (MSigDB, gsea-msigdb.org)
For visualizing possible sub-states of endothelial cells, we applied trajectory analysis
to our data, identifying pseudotemporal ordering of cells along the actual time course.
We therefore used the Monocle (Version 2.6.4) toolbox and followed the standard
pipeline, as described in their tutorial37. In brief, Seurat objects were converted into
Monocle using the “importCDS” function and size factors and dispersion were
estimated. We then defined genes as expressed, when exceeding a threshold of 0.1 and
where at least expressed in 10 cells. We then based our trajectory on differential genes
between the individual timepoints, as calculated with “differentialGeneTest”. Cells
where then accordingly filtered using “setOrderingFilter”. Pseudotime reduction of
dimension was applied with the “DDRTree” method, as implemented in the
“reduceDimension” function. Finally, we ordered cells by using “orderCells” and plotted
trajectories split by state and timepoint.
Ligand-receptor interaction analysis was performed on transcriptomic profiles25.
Briefly, a weighted directed graph with four layers of nodes was built linking source cell
types (layer 1), defined by expression of a ligand (layer 2), to target cell types (layer 4)
expressing a corresponding receptor (layer 3), after reference to a curated map of
ligand-receptor pairs. Source-ligand and receptor target edges were weighted according
to expression fold-change in ligands and receptors, respectively. Ligand-receptor edges
were further weighted by mouse-specific association scores from the STRING database.
Permutation testing (100,000 permutations) of randomized network connections was
applied to determine significant source-target network connections following
Benjamini–Hochberg multiple-testing correction (adjusted p < 0.01).
Immunohistochemistry. Male C57BL/6 J mice were sacrificed by cervical dis-
location on d3 (n= 6) and d14 (n= 5) post LAD surgery. Age-matched non-
operated animals (homeostasis) have been sacrificed on the same day (n= 4,
respectively). Hearts were flushed with HBSS (14025-050, Gibco) by injection into
the Vena cava caudalis, cut in half transversally and washed in HBSS and DPBS
(14190-094, Gibco). Tissue was fixed using 4% Paraformaldehyde (1.04005-1000,
Merck) 4 °C on an orbital shaker overnight. Hearts were cryopreserved using
increasing dilutions of 10%, 20% and 30% sucrose (S0389-1kg, Sigma) and 1%
Polyvinylpyrrolidon (PVP, P-5288, Sigma) in PBS and incubated for 24 h at 4 °C on
orbital shaker, respectively. Hearts were embedded in embedding moulds (58951,
Thermo Scientific), using 15% sucrose, 1% PVP and 8% gelatine (G1890-100G,
Sigma). Tissue was frozen at −80 °C overnight and cut in 50 μm sections. Sections
were thawed at room temperature for 30 min. Antigen retrival was performed by
boiling the sections for 15 min in citrate buffer (pH 6, 0.1 M). Quenching of
endogenous peroxidases was performed in 100% Methanol with 1% H2O2 for
40 min. Sections were blocked with 3% BSA (0163.2, Roth), 5% donkey serum
(7475, abcam), 20 mM MgCl2, and 0.3% Tween 20 (P1379, Sigma). Primary
antibodies were incubated at 4 °C overnight followed by secondary antibody
incubation for 1 h at room temperature.
For GFP stainings, we used hearts isolated from Cdh5-CrERT2;mT/mG or
Col1a2-CrERT2;mT/mG reporter mice and embedded them in O.C.T medium
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-20905-1 ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:681 | https://doi.org/10.1038/s41467-021-20905-1 | www.nature.com/naturecommunications 9
(4583, Tissue-Tek®). Hearts were cut transversally in 10 μm sections and frozen
at −80 °C and stained as described above with respective antibodies.
For HUVEC stainings, cells were cultured in μ-slide eight-well chambers
(80826, Ibidi) coated with 1 μg/mL human fibronectin (F0895, Sigma Aldrich).
After treatment, cells were pre-fixed for 2 min by adding equal amounts of 4% PFA
to the cultivation medium and subsequently fixed in 2% PFA for 20 min at room
temperature. We permeabilized and blocked cells for 1 h in blocking buffer
containing 5% donkey serum, 0.3% Triton X-100, 2% BSA. Primary antibodies
were incubated overnight in blocking buffer at 4 °C. We incubated secondary
antibodies for 1 h on room temperature in dilution buffer, containing 1% BSA, 1%
donkey serum, and 0.3% Triton X-100.
For Confettiwt/fl-Cdh5-CreERT2 animals, hearts were fixed by injection of 4%
PFA into the Vena cava caudalis and subsequent fixation in 4% PFA overnight at
4 °C. Tissue was embedded in O.C.T medium, cut transversally in 10 μm sections
and analyzed without further staining.
Used antibodies are described in the supplement (Supplementary Table 2).
Images were taken under a Zeiss LSM780 or Leica SP8 confocal microscope.
Cell culture. The in vitro experiments were performed using human umbilical vein
endothelial cells (HUVECs) purchased from Lonza. HUVECs were cultured in
endothelial basal medium (CC3121, Lonza) with all recommended supplements
(hydrocortisone (CC-4035C, Lonza), ascorbic acid (CC-4116C, Lonza), bovine
brain extract (CC-4092C, Lonza), epidermal growth factor (CC-4017, Lonza), 10%
fetal bovine serum (FBS) (CC-4101, Lonza) and Gentamicin + Amphotericin-
B-1000 (CC-4081C, Lonza)). Cells were incubated at 37 °C and 5% CO2.
Endothelial-to-mesenchymal transition assay. For the induction of endothelial-
to-mesenchymal transition (EndMT), HUVECs were cultured either in the normal
cell culture medium as described in the section “Cell Culture” (Control), or in a
medium without epidermal growth factor and bovine brain extract, supplemented
with either 10 ng/mL TGF-β2 (302-B2, R&D System), or 10 ng/mL TGF-β1 (240-B,
R&D System) and 10 ng/mL IL-1β (200-01B, Peprotech)38. Nitric oxide synthase
was inhibited by 1 mM N-Nitroarginine methyl ester (L-NAME). To reverse
EndMT induction, the medium containing the named stimuli or inhibitor was
replaced after 3, 7, or 10 days of culture with normal control medium and culti-
vated for 4 days. Medium and treatment was replenished every second day. After
day 1, 2, 3, 7, 10, 11, or 14 RNA was isolated. For cell cycle inhibition assay, we
treated the cells with 2.5 μM Vitexicarpin (CFN98172, Chem Faces) or equal
amounts of DMSO after TGF-β2 treatment for 4d.
RNA analysis. RNA was isolated using the miRNeasy-kit (217004; Qiagen).
Additional DNase I (79254; Qiagen) digestion according to the manufacturer’s
protocol was performed. 1 μg of RNA from each sample was reverse-transcribed by
MMLV Reverse Transcriptase (N8080018; Life technologies), using random hex-
amer primers (10 min at 25 °C, 15 min at 42 °C, 5 min at 99 °C) as previously
described39. We performed qPCR analysis using Fast SYBR Green Mastermix
(4385612, Life Technologies) and the ViiA7- Realtime qPCR System (Life Tech-
nologies). Expression levels were normalized to the housekeeping genes RPLP0 and
GAPDH and analyzed using the 2−ΔCt method. The sequences of the used primers
are listed in the supplement (Supplementary Table 3).
FACS Analysis. For FACS analysis, we used hearts from Cdh5 CreERT2;mT/mG
and processed them as described above for single-cell sequencing. Cells were then
fixed for 20 min in methanol on ice and blocked in 3% BSA, 5% donkey serum and
0.1% Triton-X100. We incubated cells with primary antibodies (Supplementary
Table 2) for 20 min on ice and with secondary antibodies for 30 min on ice.
Additionally, FACS was performed on 1 h 1mM BrdU treated HUVECs, using a
BrdU kit (559619,BD Pharmingen). Here, cells were fixed and permeabilized and
treated with DNAse to expose BrdU labeled DNA. Cells were stained using anti-
BrdU antibody and 7-AAD dye. All reagents supplied by the kit. Analysis was
performed on BD LSRFortessa X-20 using FACS Diva software.
Active glycolytic flux. HUVECs were seeded on a fibronectin coated Seahorse
XF96 culture plate (Agilent Technologies) at a density of 6 × 104 cells per well in
the respective endothelial growth medium. The medium was changed to Krebs
Henseleit buffer (111 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 2 mM MgSO4,
1.2 mM Na2HPO4) containing 1 mM sodium pyruvate 1 h prior to the measure-
ment with a XFe 96 extracellular flux analyzer (Agilent, Technologies). Activators
and inhibitors were used at the following final concentrations: 10 mM glucose,
1.5 μM oligomycin A, 100 mM 2-deoxy-D-glucose. Each measurement was aver-
aged from three technical replicates of three different biological replicates.
13C Glucose metabolic flux analysis. HUVEC were seeded in 10 cm culture
dishes and treated with the respective media. In all, 48 h prior to collection, media
were substituted with glucose free media, supplemented with 13 C uniformly
labeled glucose (Sigma) in a final concentration of 17 mM. Samples were collected
and prepared as previously described40. LC-MS/MS experiments were performed
on an Agilent 1290 Infinity UPLC system (Agilent, Waldbronn, Germany) coupled
to a QTrap5500 mass spectrometer (Sciex, Darmstadt, Germany), equipped with an
ESI TurboIonSpray source. The flow rate was 0.22 mL/min, autosampler tem-
perature was set at 6 °C, and the column compartment was set to 35 °C. Separations
were performed on an Asahipak NH2P-40 (250 × 2mm, 4 μm particle size; Showa
Denko, Munich, Germany). The mobile phase was composed of 20 mM ammo-
nium carbonate in H2O/5% acetonitrile (ACN), pH= 10 and ACN. After an initial
3.5 min isocratic elution of 99.9% ACN, the percentage of ACN decreased to 85%
at 3.6 min, to 75% at 8.1 min, to 0% at 14 min, back to 99.9% at 34 min. The
composition was maintained at 99.9% ACN until the 42 min. The QTrap5500-MS
system was operated in triple quadrupole mode wit positive/negative ion switching.
Ion spray voltage of 5500/-4500 V were applied, respectively. Curtain gas was set to
30 psi, collision gas to medium, source temperature to 500 °C, ion source gas 1 to
35 psi, ion source gas 2 to 35 psi. Analyst 1.6.2 and MultiQuant 3.0 (both from
Sciex, Darmstadt, Germany), were used for data acquisition and analysis,
respectively.
DNA methylation. For assessment of DNA methylation, HUVECs were cultured
as described above and DNA was isolated using the QIAamp DNA Micro Kit
(56304, Qiagen), according to the manufactures protocol.
DNA concentration was quantified using the Qubit dsDNA HS Assay kit
(Q32851, Invitrogen). 200–500 ng of DNA was used as input for DNA methylation
analysis. The Infinium Human-Methylation EPIC BeadChip (850k) (WG-317,
Illumina) was used to determine the DNA methylation status of more than 850.000
CpG sites, respectively following the producer’s guidelines. On-chip quality metrics
of all samples were carefully controlled.
Infinium human methylation EPIC array analysis was performed by using
RnBeads (vesion 2.2)41 and ADMIRE42. Raw intensities were taken from IDAT
files and quality control was performed on all probes and samples. During
preprocessing, probes and samples have been filtered for SNP-enrichment and
highest impurity using Greedycut (FDR adjusted p < 0.05). The data was
normalized using dasen method43. Individual site-based methylation levels were
calculated and subsequently used for region-based methylation level assessment
(CpG island/promoter/ tails/gene body). Differential methylated regions were
determined by comb-p method44 and the combined rank score of RnBeads. For
illustration of beta values ADMIRE visualization functions were used.
For regulatory element analysis, 848,254 CpG probes that were retained after
EPIC array quality filtering were overlapped with 2.4 million annotated regulatory
elements (REMs) of the EpiRegio database45 and analyzed using RnBeads software.
CpG methylation was averaged over all CpG probes overlapping a REM.
Differentially methylated regulatory elements with a mean methylation difference
≥0.1 between Control and +TGF-β2 (d3) or +TGF-β2 (d3) -TGF-β2 (d7)
respectively, and FDR corrected p-values ≤ 0.05 were selected. These significantly
differentially methylated REMs were clustered by their DNA methylation pattern
using hierarchical clustering.
Statistics and reproducibility. For single-cell RNA Sequencing statistical analysis
of differential gene expression was performed with Seurat’s FindMarkers or Fin-
dAllMarkers functions by using a bimodal likelihood estimator test suitable for
zero-inflated scRNA-seq data46. Data is always shown in p-values corrected for
multiple testing (Bonferroni).
For GO-Term enrichment of significantly regulated genes we used enrichR
software suite36. We used the combined score to report on enrichment, which
combines the term’s deviation to its expected rank and the p-value of Fisher’s
exact test.
For qPCR data, ANOVA non-parametric Kruskall–Wallis multiple comparison
test with posthoc Dunn´s test was used for comparison of multiple groups or a
two-sided Student’s t test with Welch’s correction. A value of p < 0.05 was
considered statistically significant.
We used a χ2-test of independence to indicate significant changes in ratios of
cell cycle assignment and considered p < 0.01 as significant.
Representative images shown have been chosen from n= 3 independent
experiments.
For Confetti;Cdh5-CreERT2 analysis we separated each border zone image
(n= 5 per animal) into 6 same size areas and counted the occurrence of colored
cells. Areas with clonal expanding cells, which had more than two times the
standard deviation of the animal mean of counted RFP, YFP and GFP cells,
were compared between the groups. We used Fisher’s exact test for statistical
analysis of the data.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The single-cell RNA−seq datasets generated in this study are available at ArrayExpress
(E-MTAB9816 and E-MTAB9817). Bulk-RNA sequencing has been deposited at
Sequencing Read Archive (PRJNA679225). RnBeads output files are available (10.6084/
m9.figshare.13247210.v1). All other data are included within the article, source data,
supplementary data or can be made available upon request. Source data are provided
with this paper.
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Code availability
Codes for R analysis of data presented in this study are available on GitHub (github.com/
TLukas1/NatComm_Tombor_et_al_2020).
Received: 28 April 2020; Accepted: 22 December 2020;
References
1. Potente, M. & Makinen, T. Vascular heterogeneity and specialization in
development and disease. Nat. Rev. Mol. Cell Biol. 18, 477–494 (2017).
2. Augustin, H. G. & Koh, G. Y. Organotypic vasculature: from descriptive
heterogeneity to functional pathophysiology. Science 357, 2379 (2017).
3. Camenisch, T. D., Schroeder, J. A., Bradley, J., Klewer, S. E. & McDonald, J. A.
Heart-valve mesenchyme formation is dependent on hyaluronan-augmented
activation of ErbB2-ErbB3 receptors. Nat. Med. 8, 850–855 (2002).
4. Dejana, E., Hirschi, K. K. & Simons, M. The molecular basis of endothelial cell
plasticity. Nat. Commun. 8, 14361 (2017).
5. MacGrogan, D. et al. How to make a heart valve: from embryonic
development to bioengineering of living valve substitutes. Cold Spring Harb.
Perspect. Med. 4, a013912 (2014).
6. Nakano, H. et al. Haemogenic endocardium contributes to transient definitive
haematopoiesis. Nat. Commun. 4, 1564 (2013).
7. Brown, A. J. et al. Role of biomechanical forces in the natural history of
coronary atherosclerosis. Nat. Rev. Cardiol. 13, 210–220 (2016).
8. Potente, M., Gerhardt, H. & Carmeliet, P. Basic and therapeutic aspects of
angiogenesis. Cell 146, 873–887 (2011).
9. De Bock, K. et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell
154, 651–663 (2013).
10. Wilhelm, K. et al. FOXO1 couples metabolic activity and growth state in the
vascular endothelium. Nature 529, 216–220 (2016).
11. Rohlenova, K. et al. Single-cell RNA sequencing maps endothelial metabolic
plasticity in pathological angiogenesis. Cell Metab. 31, 862–877.e14
(2020).
12. Goveia, J. et al. An integrated gene expression landscape profiling approach to
identify lung tumor endothelial cell heterogeneity and angiogenic candidates.
Cancer Cell 37, 421 (2020).
13. Chen, P.-Y. et al. Endothelial-to-mesenchymal transition drives
atherosclerosis progression. J. Clin. Invest. 125, 4514–4528 (2015).
14. Evrard, S. M. et al. Endothelial to mesenchymal transition is common in
atherosclerotic lesions and is associated with plaque instability. Nat. Commun.
7, 11853 (2016).
15. Zeisberg, E. M. et al. Endothelial-to-mesenchymal transition contributes to
cardiac fibrosis. Nat. Med. 13, 952–961 (2007).
16. Piera-Velazquez, S. & Jimenez, S. A. Endothelial to mesenchymal transition:
role in physiology and in the pathogenesis of human diseases. Physiol. Rev. 99,
1281–1324 (2019).
17. Fu, X. et al. Specialized fibroblast differentiated states underlie scar formation
in the infarcted mouse heart. J. Clin. Invest. 128, 2127–2143 (2018).
18. Gourdie, R. G., Dimmeler, S. & Kohl, P. Novel therapeutic strategies targeting
fibroblasts and fibrosis in heart disease. Nat. Rev. Drug Discov. 15, 620–638
(2016).
19. Welch-Reardon, K. M., Wu, N. & Hughes, C. C. W. A role for partial
endothelial-mesenchymal transitions in angiogenesis? Arterioscler. Thromb.
Vasc. Biol. 35, 303–308 (2015).
20. Manavski, Y. et al. Clonal expansion of endothelial cells contributes to
ischemia-induced neovascularization. Circ. Res. 122, 670–677 (2018).
21. Forte, E. et al. Dynamic interstitial cell response during myocardial infarction
predicts resilience to rupture in genetically diverse mice. Cell Rep. 30,
3149–3163 (2020).
22. Virag, J. I. & Murry, C. E. Myofibroblast and endothelial cell proliferation
during murine myocardial infarct repair. Am. J. Pathol. 163, 2433–2440
(2003).
23. Yingling, J. M. et al. Preclinical assessment of galunisertib (LY2157299
monohydrate), a first-in-class transforming growth factor-β receptor type I
inhibitor. Oncotarget 9, 6659–6677 (2018).
24. Xiong, J. et al. A metabolic basis for endothelial-to-mesenchymal transition.
Mol. Cell 69, 689–698.e7 (2018).
25. Farbehi, N. et al. Single-cell expression profiling reveals dynamic flux of cardiac
stromal, vascular and immune cells in health and injury. Elife 8, 43882 (2019).
26. Li, Z. et al. Single-cell transcriptome analyses reveal novel targets modulating
cardiac neovascularization by resident endothelial cells following myocardial
infarction. Eur. Heart J. 40, 2507–2520 (2019).
27. Arciniegas, E., Sutton, A. B., Allen, T. D. & Schor, A. M. Transforming growth
factor beta 1 promotes the differentiation of endothelial cells into smooth
muscle-like cells in vitro. J. Cell Sci. 103, 521–529 (1992).
28. Xu, X. et al. Epigenetic balance of aberrant Rasal1 promoter methylation and
hydroxymethylation regulates cardiac fibrosis. Cardiovasc. Res. 105, 279–291
(2015).
29. Welch-Reardon, K. M. et al. Angiogenic sprouting is regulated by endothelial
cell expression of Slug. J. Cell Sci. 127, 2017–2028 (2014).
30. Wagner, J. U. G. et al. Switch in Laminin beta2 to Laminin beta1 isoforms
during aging controls endothelial cell functions-brief report. Arterioscler.
Thromb. Vasc. Biol. 38, 1170–1177 (2018).
31. Kovacic, J. C. et al. Endothelial to mesenchymal transition in cardiovascular
disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 73, 190–209 (2019).
32. Rogg, E.-M. et al. Analysis of cell type-specific effects of microRNA−92a
provides novel insights into target regulation and mechanism of action.
Circulation 138, 2545–2558 (2018).
33. Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A global double-
fluorescent Cre reporter mouse. Genesis 45, 593–605 (2007).
34. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-
cell transcriptomic data across different conditions, technologies, and species.
Nat. Biotechnol. 36, 411–420 (2018).
35. Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma
by single-cell RNA-seq. Science 352, 189–196 (2016).
36. Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis
web server 2016 update. Nucleic Acids Res. 44, W90–W97 (2016).
37. Qiu, X. et al. Reversed graph embedding resolves complex single-cell
trajectories. Nat. Methods 14, 979–982 (2017).
38. Glaser, S. F. et al. The histone demethylase JMJD2B regulates endothelial-to-
mesenchymal transition. Proc. Natl Acad. Sci. USA 117, 4180–4187 (2020).
39. Boeckel, J.-N. et al. Jumonji domain-containing protein 6 (Jmjd6) is required
for angiogenic sprouting and regulates splicing of VEGF-receptor 1. Proc. Natl
Acad. Sci. USA 108, 3276–3281 (2011).
40. Grankvist, N. et al. Profiling the metabolism of human cells by deep (13)C
labeling. Cell Chem. Biol. 25, 1419–1427.e4 (2018).
41. Muller, F. et al. RnBeads 2.0: comprehensive analysis of DNA methylation
data. Genome Biol. 20, 55 (2019).
42. Preussner, J., Bayer, J., Kuenne, C. & Looso, M. ADMIRE: analysis and
visualization of differential methylation in genomic regions using the Infinium
HumanMethylation450 Assay. Epigenet. Chromatin 8, 51 (2015).
43. Pidsley, R. et al. Critical evaluation of the Illumina MethylationEPIC
BeadChip microarray for whole-genome DNA methylation profiling. Genome
Biol. 17, 208 (2016).
44. Pedersen, B. S., Schwartz, D. A., Yang, I. V. & Kechris, K. J. Comb-p: software
for combining, analyzing, grouping and correcting spatially correlated
P-values. Bioinformatics 28, 2986–2988 (2012).
45. Baumgarten, N. et al. EpiRegio: analysis and retrieval of regulatory elements
linked to genes. Nucleic Acids Res. 48, W193–W199 (2020).
46. Soneson, C. & Robinson, M. D. Bias, robustness and scalability in single-cell
differential expression analysis. Nat. Methods 15, 255–261 (2018).
Acknowledgements
We wish to thank Felix Vetter, Maximilian Merten, Lisa-Maria Kettenhausen and Katrin
Häfner for offering technical assistance to the authors of this study. We acknowledge BioR-
ender.com for providing templates used for illustrations. This study is supported by the
CRC1366 (Projects B4 and B1) and CRC834 (Project B5 and B13) by the Deutsche For-
schungsgemeinschaft, and the Rolf Schwiete Foundation to S.D. The German Cardiovascular
Research network DZHK supports W.T.A., Y.M., M.H.S, S.-I.B., and S.D. S.D. was supported
by a fellowship of the Australian Academy of Science. R.P.H. acknowledges research support
from the National Health and Medical Research Council of Australia (NHMRC;
APP1118576, 1074386), the Australian Research Counsel (ARC; SR110001002), Foundation
Leducq Transatlantic Networks of Excellence in Cardiovascular Research (15 CVD 03,
13 CVD 01) and the New South Wales Government Department of Health.
Author contributions
L.S.T. performed bioinformatic analyses, performed in vitro and in vivo experiments, qPCR,
immunohistochemistry, FACS and data analysis. S.F.G. performed in vitro experiments,
qPCR and FACS analysis. A.F. performed in vivo experiments. J.W., S.I.B., and I.F. per-
formed and analyzed metabolic analysis. M.M-R., G.L., and Y.M. performed immunohis-
tochemistry experiments. C.S. and T.A. performed EPIC array. N.B., K.K., M.L., and M.H.S.
analyzed EPIC array data. D.J. supported bioinformatic analysis. R.P. and R.P.H performed
and analyzed ligand-receptor analysis. E.-M.R., E.F., M.F., and N.R. provided sequencing
data and analysis strategies. W.T.A. conducted single-cell library generation. L.S.T., W.T.A.,
and S.D. designed experiments. L.S.T. and S.D. wrote the manuscript.
Funding
Open Access funding enabled and organized by Projekt DEAL.
Competing interests
The authors declare no competing interests.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-20905-1 ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:681 | https://doi.org/10.1038/s41467-021-20905-1 | www.nature.com/naturecommunications 11
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
021-20905-1.
Correspondence and requests for materials should be addressed to S.D.
Peer review information Nature Communications thanks Guido Krenning and the
other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer
reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2021
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-20905-1
12 NATURE COMMUNICATIONS |          (2021) 12:681 | https://doi.org/10.1038/s41467-021-20905-1 | www.nature.com/naturecommunications
